The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

9.1% of adverse events were reported after 180 days; a small number of manufacturers submitted most of the late reports.

A judge on Wednesday blocked President Donald Trump's administration from carrying out steep cuts to federal grant funding for medical research.